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Concise report
Burden of rheumatoid arthritis among US Medicare
population: co-morbidities, health-care resource
utilization and costs
Chieh-I Chen1, Li Wang2, Wenhui Wei3,a, Huseyin Yuce4 and Kristine Phillips5,6
Abstract
Objectives. The study aimed to assess the burden of RA among the US Medicare population (aged
65 years) by comparing co-morbidities, health-care resource utilization (HCRU) and costs against
matched non-RA Medicare patients.
Methods. Data were obtained from the Medicare fee-for-service claims database from 2010 to 2013.
RA Medicare patients were identically matched with Medicare patients without RA (controls) based on
demographics. Bivariate analyses were conducted to examine differences between cohorts for co-
morbidities, HCRU and costs. A generalized linear model was used to test relationships between
patient-level characteristics, HCRU and costs.
Results. The study population included 115 867 RA patients and 115 867 age-, sex-, race- and
region-matched non-RA controls. Mean age was 75.2 years; 79.4% were female. Co-morbidities were
greater in RA vs non-RA patients [Charlson Co-morbidity Index (excluding RA): 1.86 vs 1.00;
P< 0.0001]. All-cause annual HCRU was greater in RA vs non-RA patients. Total annual health-care
costs were 3-fold higher in RA vs non-RA patients ($20 919 vs $7197, respectively; P< 0.0001) with
the major driver of costs in the RA cohort being outpatient costs. Approximately half of the overall
costs in the RA cohort were RA related ($11 587). After controlling for differences in patient character-
istics and co-morbidities between cohorts, the adjusted total mean annual costs for RA patients were
still more than twice those of non-RA patients ($16 374 vs $6712; P< 0.0001).
Conclusions. Among US Medicare patients, those with an RA diagnosis had a significantly greater
burden of co-morbidities, HCRU and costs compared with a matched cohort without RA.
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Introduction
RA is estimated to affect 0.2–1% of the worldwide
population [1, 2]. Based on 1987 diagnostic criteria, in
the US, 0.6% of adults (18 years) and 2.0% of indi-
viduals 60 years of age are affected [3, 4], resulting in
2.9 million visits to physicians related to RA in the US
annually based on 2007 data [5]. However, the updated
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2010 criteria include in their diagnosis patients previ-
ously classified as having undifferentiated arthritis; as a
result, the number of patients with RA may be higher [6].
Although disease onset may occur at any age,
approximately one-third of all RA patients are >65 years
of age [7]. Given disease chronicity, low remission rates
(estimated to be between 8.6 and 19.6% based on vary-
ing definitions of remission [8]) and the increasing size of
the US elderly population [9], RA poses a significant
economic burden.
Pharmacological therapy is considered the mainstay of
treatment for RA [10, 11]; however, despite an abun-
dance of treatment options, elderly patients with RA are
less likely to be prescribed DMARDs, including MTX,
AZA, LEF, SSZ, HCQ, gold and minocycline, than
younger patients [12, 13]. This may be explained by the
perception that DMARDs can have greater propensity for
adverse events in this patient population. Additionally,
elderly patients may fear trying new treatments [12].
Co-morbidities associated with RA [14] are likely to fur-
ther impact clinical problems, associated health-care
resource utilization (HCRU), and direct and indirect costs
[15]. In the US, total annual health costs (including direct
and indirect costs) among the overall RA patient popula-
tion have been estimated at up to $19.3 billion (in 2005
US dollars) [16]. However, additional data on the clinical
and economic impact of RA in the US are required, espe-
cially in the elderly population, to provide better informa-
tion for health-care and health policy decision-making for
this growing patient group.
The aim of this retrospective cohort analysis was to
establish the burden of RA in the US Medicare population
(65 years old) by comparing co-morbidities, HCRU and
associated costs with a matched non-RA Medicare cohort.
Methods
Study design and sample population
Patient-level data for this observational, retrospective
cohort analysis were obtained from the anonymized
Medicare fee-for-service (FFS) claims database. Data
were collected between 1 January 2010 and 31
December 2013 for two cohorts (aged 65 years) of
Medicare beneficiaries, comprising an RA cohort and a
matched cohort without RA. Patients were included in
the RA cohort if they had made at least two RA-related
medical claims [International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) code
714.xx] 7 days apart, and had continuous health plan
enrolment with FFS medical and pharmacy benefits for
the 12-month pre-index (baseline) period until the end of
the 12-month post-index (follow-up) period. The index
date was defined as the date of the patient’s first phar-
macy claim for a DMARD. Each RA cohort patient was
matched (1:1) with a patient without RA [i.e. no diagno-
sis of RA (ICD-9-CM code 714.xx) during the study peri-
od] of identical age, sex and race, who was from the
same US region, and had continuous FFS health plan
enrolment with medical and pharmacy benefits for the
12-month baseline period and the 12-month follow-up
period (Fig. 1). These control patients were assigned the
same index date as the case patients with whom they
were matched.
Baseline data
Patient demographic characteristics were obtained at
the index date. Co-morbid conditions were assessed
throughout the 12 months pre-index date (baseline
period). Overall co-morbidity was measured using the
Charlson Co-morbidity Index (CCI) Score, which assigns
a weight ranging from one to six according to disease
severity for 19 conditions [17]. In addition, the Deyo-
modified CCI was used to allow ICD-9-CM diagnosis
codes to contribute to the score [18]. The Chronic
Disease Score was developed by Von Kroff and col-
leagues, and is an aggregate co-morbidity measure,
which is based on current medication use and serves as
an indicator of a patient’s morbidity and overall health.
The Chronic Disease Score ranges from 0 to 36, and
the higher the score, the more likely that the patient will
be hospitalized and/or die. In this study, pharmacy
claims were used to determine the Chronic Disease
Score [19]. Additionally, the severity index for RA
(SIFRAV
R
) score, which ranges from 0 to 128.5 and was
FIG. 1 Overview of study design
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assessed by an expert Delphi panel of six board-
certified, clinically active rheumatologists, was used
exclusively to measure RA severity through medical
records [20–22]. Using associated scores from the
Delphi panel, a severity index for RA was created by
calculating the weighted sum, which was then verified
by its estimation power for health-care outcomes and
utilization [20]. Using claims data, 39 indicators, includ-
ing laboratory, extra-articular manifestations, surgical
history and medication, are included. Co-morbidities in
the RA cohort (primary and secondary diagnosis) based
on the first three digits of ICD-9-CM diagnosis codes
were compared with the corresponding rates for the
non-RA cohort, and the top 10 non-bone- and joint-
related co-morbidities were reported.
Outcomes measures
During the 12-month follow-up period, all-cause (both
cohorts) and RA-related (RA cohort only) HCRU was
estimated for ambulatory (physician office and outpa-
tient) visits, emergency department (ED) visits, inpatient
admissions, length of stay (LOS) and prescription fills;
these were considered RA-related if the claim had a pri-
mary or secondary diagnosis of RA or involved use of
any RA-related medication, including CSs, NSAIDs or
DMARDs. Similarly, all-cause (both cohorts) and RA-
related (RA cohort only) health-care costs were esti-
mated for ambulatory and ED visits, inpatient
admissions and pharmacy visits. In addition, total (medi-
cal plus pharmacy) costs as paid by health plans were
also estimated. All costs were adjusted for inflation to
2013 US dollars using the annual medical care compo-
nent and drug cost component of the Consumer Price
Index.
Analysis
All patient variables, including age, sex, race, region and
baseline co-morbidity index scores, as well as all-cause
HCRU, and costs over the 12-month follow-up period,
were compared between the RA and non-RA cohorts.
The benefit of treatment on the risk of disease(s) of
interest, HCRU, and costs were also determined.
Bivariate comparisons were conducted to examine
the differences between the RA and non-RA cohorts in
co-morbidities, HCRU, and costs. For dichotomous and
polychotomous variables, P-values were calculated
using the v2 test, and for continuous variables P-values
were calculated using an unpaired t-test.
A generalized linear model (GLM) was used to test the
relationships between patient-level characteristics,
HCRU and costs. The dependent variables included
patients with total HCRUs, including inpatient, outpa-
tient, ED, office, and pharmacy visits. Independent varia-
bles included all patient demographic characteristics
(age, sex, race and region), baseline co-morbidities
(CCI, individual co-morbidities), and the cohort variable
(RA or non-RA Medicare). In addition, negative binomial
and logistic regressions were used to model HCRU
measures.
To estimate total costs, log10-transformation and
GLMs were applied, depending on the distribution and
presence of heteroscedasticity. In these models, the
dependent variables included the costs of inpatient, out-
patient, ED and office visits, and pharmacy use.
Results
Clinical characteristics and demographics
In total, 3 156 628 Medicare beneficiaries were identified
in the study period (from 1 January 2011 to 31
December 2013). Of these, 2 924 894 were excluded
because they were aged <65 years, had no continuous
health enrolment plan or had no diagnosis of RA during
the study period, resulting in a total sample size of
231 734 patients (115 867 patients in the RA Medicare
cohort and 115 867 matched patients in the non-RA
Medicare cohort; Fig. 2). Mean (S.D.) patient age was
75.2 (6.36) years; 79.4% were women; 86.4% were
Caucasian; and 41.3% resided in the Southern region of
the US (Table 1).
Co-morbidity burden
Compared with the non-RA cohort, the RA cohort had
significantly greater overall co-morbidities [CCI score
(excluding RA) 1.86 vs 1.00; P< 0.0001; Table 1].
Likewise, the chronic disease score (8.50 vs 5.54;
P<0.0001) and severity index for RA (19.43 vs 0.51;
P<0.0001) were significantly higher in the RA cohort vs
the non-RA cohort (Table 1).
The most common non-bone- and joint-related diag-
noses in both cohorts were cardiovascular system
related, with 76.4% of patients in the RA cohort and
44.8% in the non-RA cohort experiencing essential
hypertension (ICD-9-CM:401), 66.4 and 41.7%, experi-
encing disorders of lipid metabolism (ICD-9-CM:272),
27.5 and 14.5% experiencing ischemic heart disease
(ICD-9-CM:414.9), and 21.0 and 9.6% experiencing
peripheral vascular disease (ICD-9-CM:443.9), respec-
tively. Other common co-morbidities included: general
symptoms (ICD-9-CM:780; code includes sleep distur-
bances and fatigue) in 50.3 and 24.3%; symptoms
involving the respiratory system and other chest symp-
toms (ICD-9-CM:786) in 48.1 and 22.1%; and other dis-
orders of the soft tissues (ICD-9-CM:729) in 45.4 and
17.4%, respectively. Furthermore, across the 10 most
common co-morbidities in both groups, the relative risk
of the co-morbidity was significantly greater for the RA
cohort vs the non-RA cohort (P< 0.0001; Table 1).
Health-care resource utilization and costs
Compared with the non-RA cohort, mean annual all-
cause HCRU, including percentage of patients with
inpatient/ED visits, outpatient visits and pharmacy visits
(as well as the mean number of these visits in the 1-year
follow-up period), were all significantly greater
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(P<0.0001) for the RA cohort than the non-RA cohort
(Fig. 3). For example, in the RA cohort there were 0.96
inpatient/ED visits during the 1-year follow-up overall,
whereas in the non-RA cohort there were 0.40 visits
(P<0.0001; Fig. 3). Moreover, RA-related HCRU was a
major driver of the overall HCRU in each case (Fig. 3).
The mean (S.D.) inpatient LOS per visit was also signifi-
cantly greater in the RA cohort compared with the non-
RA cohort [4.38 (16.2) vs 0.97 (4.92) days, respectively;
P<0.0001], with the mean LOS specifically related to
RA in the RA cohort being 2.66 (10.77) days.
Mean annual total health-care costs were 3-fold
higher for the RA cohort compared with the non-RA
cohort ($20 919 vs $7197, respectively; P< 0.0001), and
more than half of the total costs were related to RA
($11 587; Fig. 4). Among the RA cohort, the main driver
for increased costs was outpatient costs, followed by
inpatient costs and then pharmacy costs. Mean annual
all-cause outpatient costs were $9022 in the RA cohort
vs $2607 in the non-RA cohort (P< 0.0001), and more
than half ($4719) of the outpatient costs in the RA cohort
were RA related (Fig. 4).
Overall pharmacy costs (calculated from Medicare
Part D) were significantly greater in the RA cohort
($5794) than the non-RA cohort ($2449; P<0.001).
However, among the RA cohort, pharmacy costs
accounted for the smallest proportion of the total costs,
with an even smaller proportion ($2670 out of $5794)
related to RA (Fig. 4). The cost of biologics [calculated
from pharmacy (Medicare Part D) plus medical
(Medicare Part B) claims] accounted for the majority of
drug-related costs [calculated from pharmacy (Medicare
Part D) plus medical (Medicare Part B) claims] observed
in all RA patients ($2836 out of $3331).
After controlling for differences in patient characteris-
tics and co-morbidities, the adjusted mean annual total
costs for the RA cohort remained more than twice those
observed in the non-RA cohort ($16 374 vs $6712,
respectively; P<0.0001; Table 2).
Discussion
Given the high and growing prevalence of RA in the eld-
erly population, it is important to establish its age- and
disease-specific clinical and economic burden to
successfully aid health-care decision-making and cost
containment in this vulnerable population.
The significantly higher incidence of co-morbidities
associated with RA has previously been reported among
adult RA patients [23–28]; however, to our knowledge
this is the first study to examine co-morbidities, HCRU
and costs specifically in the RA Medicare population in
a real-world setting. The results of this retrospective
cohort study indicated that RA Medicare patients have a
significantly higher prevalence of non-bone- and joint-
related co-morbidities, including a higher incidence of
cardiovascular co-morbidities, such as hypertension,
disorders of lipid metabolism, ischemic heart disease
and peripheral vascular disease, as well as symptoms
involving the respiratory system, in comparison with a
matched non-RA cohort.
FIG. 2 Patient attrition scheme
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As expected based on the higher incidence of co-
morbidities, HCRU was significantly higher in the RA
Medicare cohort than in the non-RA Medicare cohort,
resulting in nearly 3-fold higher annual health-care costs,
with RA-related costs accounting for slightly more than
half of the total costs in the RA cohort. Significant differ-
ences between the RA Medicare cohort and the non-RA
Medicare cohort were observed across medical (outpa-
tient and inpatient/ED) and pharmacy costs. Increased
pharmacy costs in the RA cohort might be expected
given the recent greater understanding of RA disease
pathogenesis and corresponding development of tar-
geted biologic and non-biologic synthetic DMARD treat-
ments [29]. For example, a 2008 analysis of prescribing
patterns identified an increase in biologic use in the US
from 3% of RA patients in 1999 to 26% of RA
patients in 2006 [30]. Importantly, this increased use of
biologics appears to have translated into an increase in
the proportion of patients achieving disease remission
[8, 31].
Although the increase in remission rates is encourag-
ing, it is possible that the cost of biologics would be a
TABLE 1 Baseline demographic and clinical characteristics for patients with and without RA
Demographic/clinical
characteristics
Control group
(non-RA)
(n5 115 867)
Case group (RA)
(n5 115 867)
P-value RR (95% CI)
Age, mean (S.D.), years 75.2 (6.4) 75.2 (6.4) – –
65–69 years, n (%) 25 653 (22.1) 25 653 (22.1) – –
70–74 years, n (%) 34 891 (30.1) 34 891 (30.1) – –
75–79 years, n (%) 26 083 (22.5) 26 083 (22.5) – –
80 years, n (%) 29 240 (25.2) 29 240 (25.2) – –
Sex, n (%)
Male 23 896 (20.6) 23 896 (20.6) – –
Female 91 971 (79.4) 91 971 (79.4) – –
Race, n (%)
White 100 160 (86.4) 100 160 (86.4) – –
Black 8709 (7.5) 8709 (7.5) – –
Asian 1816 (1.6) 1816 (1.6) – –
Hispanic 2970 (2.6) 2970 (2.6) – –
North American 604 (0.5) 604 (0.5) – –
Other 1608 (1.4) 1608 (1.4) – –
Geographical location, n (%)
Northeast 19 639 (16.9) 19 639 (16.9) – –
Midwest 28 334 (24.5) 28 334 (24.5) – –
South 47 877 (41.3) 47 877 (41.3) – –
West 19 777 (17.1) 19 777 (17.1) – –
Other 240 (0.2) 240 (0.2) – –
Baseline co-morbid conditions, mean (S.D.)
CCI (excluding RA) 1.00 (1.77) 1.86 (2.02) <0.0001 –
Chronic disease score 5.54 (3.68) 8.50 (3.66) <0.0001 –
Severity index for RA (SIFRA) 0.51 (1.94) 19.43 (15.60) <0.0001 –
Common baseline non-bone- and joint-related
diagnoses, n (%)
Essential hypertension (ICD-9-CM: 401) 51 897 (44.79) 88 565 (76.44) <0.0001 1.71 (1.69, 1.72)
Disorders of lipid metabolism (ICD-9-CM:272) 48 346 (41.73) 76 934 (66.40) <0.0001 1.59 (1.58, 1.60)
General symptoms (ICD-9-CM:780) 28 136 (24.28) 58 218 (50.25) <0.0001 2.07 (2.05, 2.09)
Symptoms involving respiratory system
(ICD-9-CM:786)
25 634 (22.12) 55 782 (48.14) <0.0001 2.18 (2.15, 2.20)
Other disorders of soft tissues (ICD-9-CM:729) 20 101 (17.35) 52 550 (45.35) <0.0001 2.61 (2.58, 2.65)
Cataract (ICD-9-CM:366) 22 212 (19.17) 43 122 (37.22) <0.0001 1.94 (1.91, 1.97)
Other unspecified anemias (ICD-9-CM:285) 13 121 (11.32) 36 882 (31.83) <0.0001 2.81 (2.76, 2.86)
Diseases of esophagus (ICD-9-CM:530) 15 212 (13.13) 35 859 (30.95) <0.0001 2.36 (2.32, 2.40)
Acquired hypothyroidism (ICD-9-CM:244) 16 859 (14.55) 33 528 (28.94) <0.0001 1.99 (1.96, 2.02)
Diabetes mellitus (ICD-9-CM:250) 22 162 (19.13) 32 748 (28.26) <0.0001 1.48 (1.46, 1.50)
Baseline RA-related therapies, n (%)
NSAIDs 25 746 (22.2) 45 958 (39.7) <0.0001 –
CSs 147 (0.1) 31 246 (27.0) <0.0001 –
DMARDs (including biologics) 3131 (2.7) 101 876 (87.9) <0.0001 –
CCI: Charlson co-morbidity index; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification;
RR: relative risk.
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significant concern for health-care budget-holders, and
their use may be discouraged without adequate informa-
tion on disease burden and treatment patterns in the
real-world setting. In the present study, pharmacy costs
accounted for only 23% ($2670) of the overall RA-
related costs, with the major driver of costs being medi-
cal costs (outpatient costs represented 41% and inpa-
tient/ED costs represented 36% of overall RA-related
costs). In addition, in this real-world study, the cost of
biologics across the overall RA cohort (e.g. infliximab,
etanercept, adalimumab, golimumab, certolizumab, aba-
tacept, anakinra, rituximab and tocilizumab) accounted
for less than a quarter of the overall difference in
costs between the RA and non-RA cohort. Moreover,
pharmacy costs represented a smaller proportion of the
total RA-related costs than they did in the total overall
cost in the RA cohort (23 vs 27%). Instead, the largest
component of increased overall costs within the RA
Medicare cohort was outpatient costs.
Similar to the present study, a study conducted by
Wolfe et al. [32] in 1986 found medical costs to be the
biggest driver of costs among patients with severe RA,
although in their study, conducted before the availability
of biologics, a majority (66%) of direct medical costs were
found to be attributable to inpatient hospitalization costs.
The reason for this outcome is likely to stem from surgical
treatment to relieve severe pain and improve the function
of severely deformed joints, management of medication
side-effects, and the management of severe co-morbid-
ities such as cardiovascular events [33]. As shown in the
FIG. 3 Percentage of all-cause and RA-related visits during the 1-year follow-up (A) and mean (S.D.) number of all-
cause and RA-related visits during the 1-year follow-up (B)
*All P-values between all-cause non-RA Medicare patients and all-cause RA Medicare patients were <0.0001. ED:
emergency department.
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present study, patients with RA have a higher rate of co-
morbidities, including a higher incidence of cardiovascular
events, than patients without RA.
Overall, the present study shows that HCRU is signifi-
cantly greater among RA patients compared with non-
RA patients. In addition, there is a relatively high total
cost for care, including the cost of biologics. These
results highlight the importance of RA from a societal
perspective, and we hope that they will be useful for
future research, including cost-effectiveness analyses.
A strength of this study is that it reflects real-world
management patterns in a large cohort of RA Medicare
patients, but studies based on claims data may have
some limitations. Firstly, the population included in this
analysis was limited only to FFS enrollees, meaning that
the cohort may not be representative of the full
Medicare population. Secondly, the costs for medical
services reimbursed by insurers other than Medicare
paid solely by beneficiaries out of pocket may not be
captured, thereby potentially underestimating the cost
burden. In the study, outpatient costs rather than phar-
macy costs were considered the main driver for the eco-
nomic burden of RA; however, the reason for the
outpatient visit is not known, and it cannot be dis-
counted that some of the outpatient costs might be
attributed to attendance for the administration of inject-
able biologics. Furthermore, it is also possible that i.v.
RA biologics could be covered under medical benefits
instead of pharmacy benefits, meaning that the cost of
prescription fills could have been underestimated.
Finally, there is a potential for inaccuracies in assigning
RA and capturing co-morbidities, as the presence of an
ICD-9-CM diagnosis code on a medical claim may not
automatically indicate the presence of disease.
FIG. 4 Mean annual all-cause and RA-related health-care costs in the Medicare population
*All P-values between all-cause non-RA Medicare patients and all-cause RA Medicare patients were <0.0001. †ED
visits accounted for all-cause $107 and RA-related $37 in the RA Medicare cohort and $51 in the non-RA Medicare
cohort. ED: emergency department.
TABLE 2 Generalized linear model-adjusted follow-up all-cause health-care utilization and costs
All-cause follow-up health-care costs, $ Control group (non-RA) S.E. Case group (RA) S.E. P-value
Inpatient/ED cost 1602 5 3973 12 <0.001
Outpatient cost 2091 6 7109 22 <0.001
Pharmacy cost 2523 8 4928 16 <0.001
Total cost (inpatient, outpatient, pharmacy) 6712 21 16 374 51 <0.001
RA-related drug cost (based on Jcode and NDC) 104 0 3080 10 <0.001
Biologics-related drug costs (based on Jcode and NDC) 15 0 3103 11 <0.001
ED: emergency department; Jcode: Healthcare Common Procedure Coding System Level II codes mainly used for infu-
sions, injections, that is, drugs that are not given orally; NDC: National Drug Code.
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Conclusion
Among US Medicare patients, RA diagnosis is associated
with a significantly greater burden of co-morbidities,
HCRU and costs when compared with a matched cohort
of non-RA Medicare patients. The annual all-cause
health-care costs in Medicare RA patients were 3-fold
higher than those of the cohort without RA; this differ-
ence was mainly attributed to increased outpatient costs,
which accounted for nearly half of the total cost. When
considering RA-related costs alone, outpatient visits
remained a major driver of costs, with pharmacy costs
representing only 23% of the total RA-related costs.
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